Fatty liver drug hope: semaglutide shows promise in Long-Term study
NCT ID NCT06983171
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well the diabetes drug semaglutide works for people with metabolic fatty liver disease (MAFLD) and liver scarring. About 70 adults will take the drug for 3 years as part of their regular care. The goal is to see if it can reduce liver fat, inflammation, and scarring, which could help prevent serious liver damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAFLD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center of Target Therapy LLC.
Moscow, 125008, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a malaria drug melt liver fat? new trial investigates
- Reishi mushroom tested as fatty liver treatment in new study
- Gut health and gym: new combo tackles fatty liver
- Fatty liver mystery: 1,000 rural bangladeshis to be screened
- Could a daily pill slow kidney failure in fatty liver patients?
- Fatty liver may cloud surgical imaging, new study finds